Has David Erb received payments from drug or device companies?

Yes. Drug and device makers reported $7,491,060 in general payments to David Erb across 3,940 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean David Erb did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about David Erb come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

David Erb

Pulmonary Disease · Spartanburg, SCNPI 1952366478

Payments from drug & device makers

$7,491,060in general payments, 2019–2025

Across 3,940 payments — averaging $1901.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Modernatx, Inc.$2.7M
AstraZeneca$908K
Seqirus USA Inc$888K
Boehringer Ingelheim$701K
Eli Lilly$418K
Johnson & Johnson$300K
plus $1.6M from 45 others

$85,871in research payments, 2019–2025

Across 12 payments — averaging $7155.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$76K
Pfizer$9K
Novavax Inc$1K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Modernatx, Inc.	2,088	$2,703,209
AstraZeneca	77	$907,556
Seqirus USA Inc	747	$888,038
Boehringer Ingelheim	100	$700,686
Eli Lilly	11	$418,490
Johnson & Johnson	38	$299,606
Pfizer	25	$182,599
Roche Diagnostics Operations, Inc.	5	$169,121
Regeneron	14	$162,729
Genentech, Inc.	28	$160,643
Novavax Inc	16	$159,859
Sanofi US Services Inc.	52	$149,128
Mylan Specialty L.p.	31	$133,990
GSK	111	$128,692
Verona Pharma, Inc.	10	$104,143
Currax Pharmaceuticals LLC	24	$101,126
Teva Pharmaceuticals USA, Inc.	25	$40,553
Boehringer Ingelheim Pharma GmbH & Co.kg	6	$30,046
Boehringer Ingelheim International GmbH	174	$22,750
Chiesi USA, Inc.	7	$18,217
Astrazeneca AB	1	$3,258
Genentech USA, Inc.	15	$1,343
Electromed, Inc.	70	$819
Actelion Pharmaceuticals US, Inc.	23	$526
Gilead	25	$488
Grifols USA, LLC	34	$481
Philips North America LLC	23	$426
Sunovion Pharmaceuticals Inc.	29	$399
Sanofi	20	$335
Insmed, Inc.	25	$314
Takeda Pharmaceuticals U.S.A., Inc.	13	$235
Regeneron Healthcare Solutions, Inc.	11	$234
Amgen	9	$157
United Therapeutics Corporation	7	$142
Novartis	8	$139
Advanced Respiratory, Inc	4	$78
Resmed Corp	5	$77
ANI Pharmaceuticals, Inc.	5	$67
Circassia Inc.	4	$61
Jazz Pharmaceuticals Inc.	2	$43
Bayer	3	$43
Inogen, Inc.	3	$41
Mallinckrodt Hospital Products Inc.	2	$38
Pulmonx Corporation	2	$33
Merck	2	$29
Body Vision Medical Inc.	1	$23
Tetraphase Pharmaceuticals, Inc.	1	$15
Vapotherm Inc	1	$13
Shire North American Group Inc	1	$12
Nabriva Therapeutics, PLC	1	$11
Novo Nordisk AS	1	$1

How this compares

$7,491,060 in reported general payments places this provider in the 95th percentile of 192 pulmonary disease providers in South Carolina.

See all pulmonary disease providers in South Carolina →

Other pulmonary disease in Spartanburg

Charles FogartySpartanburg$18.7M
Farhan SiddiquiSpartanburg$8.6M
Joseph BosciaSpartanburg$7.9M
Gregory FeldmanColumbia$15.1M
Charles ThompsonAnderson$7.7M
Richard BoganColumbia$4.8M
Patrick FlumeCharleston$4.6M
Michael DenenbergRock Hill$3.1M
Abhijit RavalAnderson$3M
Nancy PatelClinton$2.6M

See the full list for South Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →